SI20026B - Heptapeptidni analogi - antagonisti oksitocina - Google Patents
Heptapeptidni analogi - antagonisti oksitocina Download PDFInfo
- Publication number
- SI20026B SI20026B SI9720076A SI9720076A SI20026B SI 20026 B SI20026 B SI 20026B SI 9720076 A SI9720076 A SI 9720076A SI 9720076 A SI9720076 A SI 9720076A SI 20026 B SI20026 B SI 20026B
- Authority
- SI
- Slovenia
- Prior art keywords
- abu
- asn
- ile
- mpa
- ch2oh
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (18)
- -Ί- Heptapeptidni analogi - antagonisti oksitocina PATENTNI ZAHTEVKI 1. Heptapeptidni analog ali njegova farmacevtsko sprejemljiva sol, ki ima oksitocin antagonistično učinkovitost ter obstaja iz heksapeptidnega dela S in C-terininalnega β-aminoalkoholnega ostanka Z, vezanega na del S z amidno vezjo, pri čemer je β-aminoalkohol Z: -NR-CH-CHjOH (Z) Q v kateri Q stoji za -(CH2)n-NH-A, n je 1-6 in A je H ali -C(=NH)NH2> in kjer R stoji za CH3 ali C 2¾ in del S je: Mpa-X-Ile-Y-Asn-Abu- (S) l_I kjer imajo Mpa, Ile, Asn in Abu naslednje pomene: Mpa ostanek 3-merkaptopropionske kisline lle ostanek izolevcina Asn ostanek asparagina Abu ostanek α-aminomaslene kisline; in kjer je D-aromatska α-aminokislina; in je alifatska a-aminokislina. X Y -2-
- 2. Heptapeptidni analog po zahtevku 1, značilen po tem, daje X amino acilni ostanek D-triptofana ali p-(2-naftil)-D-alanina.
- 3. Heptapeptidni analog po zahtevku 2, značilen po tem, da je Y amino acilni ostanek levcina, valina, izolevcina, aloizolevcina, β,β-dietilalanina, cikloheksilalanina ali cikloheksilglicina.
- 4. Heptapeptidni analog po zahtevku 1, značilen po tem, daje Y amino acilni ostanek levcina, valina, izolevcina, aloizolevcina, β,β-dietilalanina, cikloheksilalanina ali cikloheksilglicina.
- 5. Heptapeptidni analog po zahtevku 4, značilen po tem, daje n enak 2, 3 ali 4.
- 6. Heplapeptidni analog po zahtevku 1, značilen po tem, daje n enak 2, 3 ali 4.
- 7. Heptapeptidni analog po zahtevku 6, značilen po tem, da je X amino acilni ostanek D-triptofana ali β-(2-naftil)-D-alanina.
- 8. Heptapeptidni analog po zahtevku 1, značilen po tem, daje X amino acilni ostanek D-triptofana ali β-(2-η3ίΐί1)-0-3ΐ3ηϊηη, Y je amino acilni ostanek levcina, valina, izolevcina, aloizolevcina, β,β-dietilalanina, cikloheksilalanina ali cikloheksilglicina, in n stoji za 2, 3 ali 4.
- 9. Heptapeptidni analog po zahtevku 8, značilen po tem, daje izbran izmed: M^a-D-Trp-Ile-aloi le-Asn-Abu-N-CH-CH2OH CH3 CH2CH2CH2NH2 Mpa-D-Trp-Ile-aloIle-Asn-Abu-N-CH-CH2OH CHj CHzCHzCHjCHjNHz - 3~ Mjja-D-Trp-Ile-aloIle-Asn-Abu-N-CH-CH2OH CHj CH2CH2NH2 Hpa-D-Trp-Ile- alolle -Asn-Abu-N-CH-CH2OH 1-1 | | CHj ch2ch2ch2nh-c=nh I nh2 Mpa-D-Trp-Ile-Ala (3, 3-dietll . )-Asn-Abu-N-CH-CH2OH *--1 I I ch3 ch2ch2ch2nh2 Mpa-D-Nal-Ile- alolle -Asn-Abu-N-CH-CH2OH CHj CH2CH2CH2NH2 Mpa-D-Nal-Ile-Ala (3, 3- dietil ) -Asn-Abu-N-CH-CH2OH I-1 I I CH3 CH2CH2CH2NH2 J I I ch3 ch2ch2ch2nh2 M^a-D-Trp-Ile-Ile-Asn-Abu-N-CH-CH2OH Mpa-D-Trp-I le-Leu-Asn-Abu-N-CH-CH2OH l___I I CHj CH2CH2CH2NH2 J Mpa-D-Trp-I1e-Val-Asn-Abu-N-CH-CH2OH CH, CH2CH2CH2NH2 Mpa-D-Trp-Ile-Cha-Asn-Abu-N-CH-CH2OH CHj CH2CH2CH2NH2
- 10. Heptapeptidni analog po zahtevku 1, značilen po tem, da ima strukturo: M l a-D-Trp-Ile- alolle -Asn-Abu-N CH-CH2OH CHj CH2CH2CH2NHz -4-
- 11. Heptapeptidni analog po zahtevku 1, značilen po tem, da ima strukturo: Mpa-D-Trp-Ile-· alolle -Asn-Abu-N CH CH2OH Ϊ-1-1 I I CH, ch,ch2ch,ch,nh,
- 12. Heptapeptidni analog po zahtevku 1, značilen po tem, da ima strukturo: Mpa-D-Trp-Ile- alolle -Asn-Abu-N-CH-CH2OH Ϊ-1 | I CH3 CH2CH2CH2NH-C=NH I nh2
- 13. Heptapeptidni analog po zahtevku 1, značilen po tem, da ima strukturo: Mpa-D-Nal-Ile-Ala (3, 3- dietil ) -Asn-Abu-N-CH-CH2OH -1 | | CH3 CH2CH2CH2NH2
- 14. Heptapeptidni analog po zahtevku 1, značilen po tem, da ima strukturo: Mpa-D-Nal-Ile- alolle -Asn-Abu-N-CH-CH2OH CH3 CH2CH2CH2NH2
- 15. Farmacevtski sestavek, značilen po tem, da obsega farmakološko učinkovito množino heptapeptidnega analoga po zahtevku 1, in farmacevtsko sprejemljiv nosilec.
- 16. Sestavek po zahtevku 15, značilen po tem, daje vodna raztopina za nazalno, subkutano ali intravenozno dajanje.
- 17. Sestavek po zahtevku 15, značilen po tem, da nosilec vključuje pufrsko sredstvo.
- 18. Sestavek po zahtevku 15, značilen po tem, da je v obliki tablete, kapsule, granul in podobnega, za oralno dajanje. Ί9· Postopek za pripravo heptapeptidnega analoga ali njegove farmacevtsko sprejemljive soli, ki imajo oksitocin-antagonistično učinkovitost in obstajajo iz heksapeplidnega dela S in C-terminalnega β-aminoalkoholnega ostanka Z, vezanega na del S z amidno vezjo, pri čemer je β-aminoalkohol Z: (Z) -NR-CH-CHjOH I Q v kateri Q stoji za -(CP^n-NH-A, n je 1-6 in A je H ali -C(=NH)NH2, in kjer R stoji za CHj ali C2H5; in del S je: (S) Mpa-X-Ile-Y-Asn-Abu-I_I kjer imajo Mpa, Ilc, Asn in Abu naslednje pomene: Mpa ostanek 3-merkaptopropionske kisline Ile ostanek izolevcina Asn ostanek asparagina Abu ostanek α-aminomaslcne kisline; in kjer X je D-aromatska α-aminokislina; in Y je alifatska a-aminokislina. z redukcijo ustrezne spojine, v kateri L stoji za Y: -NR1-CH-CO-OBn (Y) H -6- v kateri M stoji za (CH2)n-N(Pht) ali -(CH2)n-N(P)-C(=NP)NP2, dve izmed skupin P zaščitna skupina za dušik, ostale pa so vodik, n je CH3 ali C2H5, z uporabo borohidridne soli ali substiluiranega boroliidrida ali borana. 20. Postopek po zahtevku 19» značilen po tem, daje borohidrid NaBILt.v kateri je ena ali l-6, R1 pa stoji za
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604341A SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Hepta-peptide oxytocin analogue |
| PCT/SE1997/001968 WO1998023636A1 (en) | 1996-11-26 | 1997-11-21 | Heptapeptide oxytocin analogues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20026A SI20026A (sl) | 2000-02-29 |
| SI20026B true SI20026B (sl) | 2000-06-30 |
Family
ID=20404757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9720076A SI20026B (sl) | 1996-11-26 | 1997-11-21 | Heptapeptidni analogi - antagonisti oksitocina |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6143722A (sl) |
| EP (1) | EP0938496B1 (sl) |
| JP (1) | JP3405460B2 (sl) |
| KR (1) | KR100463132B1 (sl) |
| CN (1) | CN1129606C (sl) |
| AR (1) | AR008531A1 (sl) |
| AT (1) | ATE242264T1 (sl) |
| AU (1) | AU713424B2 (sl) |
| BR (1) | BR9713366B1 (sl) |
| CA (1) | CA2272990C (sl) |
| CZ (1) | CZ299532B6 (sl) |
| DE (1) | DE69722651T2 (sl) |
| DK (1) | DK0938496T3 (sl) |
| EE (1) | EE03832B1 (sl) |
| ES (1) | ES2203823T3 (sl) |
| HK (1) | HK1022481A1 (sl) |
| HR (1) | HRP970630B1 (sl) |
| HU (1) | HU228568B1 (sl) |
| IL (1) | IL129519A (sl) |
| LT (1) | LT4650B (sl) |
| LV (1) | LV12350B (sl) |
| MY (1) | MY125555A (sl) |
| NO (1) | NO321380B1 (sl) |
| NZ (1) | NZ336445A (sl) |
| PL (1) | PL189292B1 (sl) |
| PT (1) | PT938496E (sl) |
| RO (1) | RO120772B1 (sl) |
| RU (1) | RU2180668C2 (sl) |
| SE (1) | SE9604341D0 (sl) |
| SI (1) | SI20026B (sl) |
| SK (1) | SK283800B6 (sl) |
| TR (1) | TR199901028T2 (sl) |
| UA (1) | UA54459C2 (sl) |
| WO (1) | WO1998023636A1 (sl) |
| ZA (1) | ZA9710518B (sl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| US6476072B1 (en) * | 2000-11-21 | 2002-11-05 | Arthur Vanmoor | Method of treating menstrual pain by enhancing the effectiveness of the human immune system |
| DE60309847T2 (de) * | 2002-02-27 | 2007-10-18 | Ferring B.V. | Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga |
| EP1504268A2 (en) * | 2002-05-02 | 2005-02-09 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr) |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| UA76639C2 (uk) * | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій |
| EP1530967B1 (en) * | 2003-11-13 | 2006-05-03 | Ferring B.V. | Blister pack and solid dosage form comprising desmopressin |
| EP1555029A1 (en) | 2004-01-19 | 2005-07-20 | Ferring B.V. | Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension |
| US20060171909A1 (en) * | 2005-02-03 | 2006-08-03 | The Procter & Gamble Company | Cosmetic compositions comprising colorants with low free dye |
| SE528446C2 (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
| KR101522747B1 (ko) | 2007-08-06 | 2015-05-26 | 알레간 인코포레이티드 | 데스모프레신 약물 전달을 위한 방법 및 장치 |
| NZ587817A (en) * | 2008-03-31 | 2012-05-25 | Ferring Bv | Oxytocin analogues |
| LT2712622T (lt) | 2008-05-21 | 2016-09-26 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas nikturijos netrikdomo miego pirminio periodo pailginimui |
| US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
| US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| AU2011278038B2 (en) | 2010-07-15 | 2017-02-02 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| ES2742299T3 (es) | 2011-03-09 | 2020-02-13 | Jitsubo Co Ltd | Nuevos péptidos entrecruzados que contienen una estructura entrecruzada no peptídica, método para sintetizar péptidos entrecruzados y nuevo compuesto orgánico utilizado en el método |
| CN102875650B (zh) * | 2012-09-26 | 2014-06-11 | 深圳翰宇药业股份有限公司 | 巴卢西班的制备方法 |
| US9365615B2 (en) | 2013-09-09 | 2016-06-14 | Jitsubo Co., Ltd. | Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method |
| EP3037101B1 (en) | 2014-12-22 | 2019-03-06 | Ferring B.V. | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| EP3359557A1 (en) | 2015-10-06 | 2018-08-15 | Ferring B.V. | New methods for making barusiban and its intermediates |
| RS63286B1 (sr) | 2016-01-04 | 2022-06-30 | ObsEva SA | Istovremeno davanje alfa-amino estra hidroksipropiltiazolidin karboksamidnog derivata i tokolitičkog agensa |
| MX2019000498A (es) | 2016-07-21 | 2019-09-16 | ObsEva SA | Regímenes de dosis de antagonista de oxitocina para promover la implantación embrionaria y prevenir abortos espontaneos. |
| WO2021043726A1 (en) | 2019-09-03 | 2021-03-11 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| EP4103750A1 (en) | 2020-02-10 | 2022-12-21 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2036973A1 (en) * | 1990-02-27 | 1991-08-28 | Mark G. Bock | Cyclic hexapeptide oxytocin antagonists |
| SE9002384D0 (sv) * | 1990-07-09 | 1990-07-09 | Ferring Ab | Derivat av baklobshormoner |
| SE501678C2 (sv) * | 1993-07-13 | 1995-04-10 | Ferring Bv | Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid |
| SE523819C2 (sv) | 1994-01-27 | 2004-05-18 | Per-Ingvar Nilsson | Accelerationsmunstycke samt metod för dess användning |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| SE9500249L (sv) | 1995-01-25 | 1996-03-25 | Valeo Engine Cooling Ab | Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan |
-
1996
- 1996-11-26 SE SE9604341A patent/SE9604341D0/xx unknown
-
1997
- 1997-11-21 NZ NZ336445A patent/NZ336445A/en not_active IP Right Cessation
- 1997-11-21 HR HR970630A patent/HRP970630B1/xx not_active IP Right Cessation
- 1997-11-21 TR TR1999/01028T patent/TR199901028T2/xx unknown
- 1997-11-21 SI SI9720076A patent/SI20026B/sl unknown
- 1997-11-21 DE DE69722651T patent/DE69722651T2/de not_active Expired - Lifetime
- 1997-11-21 JP JP52460298A patent/JP3405460B2/ja not_active Expired - Lifetime
- 1997-11-21 CN CN97180014A patent/CN1129606C/zh not_active Expired - Fee Related
- 1997-11-21 AT AT97946210T patent/ATE242264T1/de active
- 1997-11-21 SK SK704-99A patent/SK283800B6/sk not_active IP Right Cessation
- 1997-11-21 PL PL97333876A patent/PL189292B1/pl unknown
- 1997-11-21 ES ES97946210T patent/ES2203823T3/es not_active Expired - Lifetime
- 1997-11-21 IL IL12951997A patent/IL129519A/en not_active IP Right Cessation
- 1997-11-21 AU AU51429/98A patent/AU713424B2/en not_active Expired
- 1997-11-21 HU HU0000577A patent/HU228568B1/hu unknown
- 1997-11-21 PT PT97946210T patent/PT938496E/pt unknown
- 1997-11-21 RO RO99-00593A patent/RO120772B1/ro unknown
- 1997-11-21 EE EEP199900210A patent/EE03832B1/xx unknown
- 1997-11-21 BR BRPI9713366-3A patent/BR9713366B1/pt not_active IP Right Cessation
- 1997-11-21 EP EP97946210A patent/EP0938496B1/en not_active Expired - Lifetime
- 1997-11-21 KR KR10-1999-7004449A patent/KR100463132B1/ko not_active IP Right Cessation
- 1997-11-21 CA CA002272990A patent/CA2272990C/en not_active Expired - Lifetime
- 1997-11-21 RU RU99113364/04A patent/RU2180668C2/ru active
- 1997-11-21 UA UA99042410A patent/UA54459C2/uk unknown
- 1997-11-21 ZA ZA9710518A patent/ZA9710518B/xx unknown
- 1997-11-21 WO PCT/SE1997/001968 patent/WO1998023636A1/en active IP Right Grant
- 1997-11-21 US US09/308,912 patent/US6143722A/en not_active Expired - Lifetime
- 1997-11-21 CZ CZ0183299A patent/CZ299532B6/cs not_active IP Right Cessation
- 1997-11-21 DK DK97946210T patent/DK0938496T3/da active
- 1997-11-25 MY MYPI97005691A patent/MY125555A/en unknown
- 1997-11-26 AR ARP970105543A patent/AR008531A1/es active IP Right Grant
-
1999
- 1999-04-30 LV LVP-99-77A patent/LV12350B/en unknown
- 1999-05-11 LT LT99-052A patent/LT4650B/lt not_active IP Right Cessation
- 1999-05-26 NO NO19992532A patent/NO321380B1/no not_active IP Right Cessation
-
2000
- 2000-03-07 HK HK00101422A patent/HK1022481A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20026B (sl) | Heptapeptidni analogi - antagonisti oksitocina | |
| RU99113364A (ru) | Гептапептидные аналоги окситоцина | |
| AU669856B2 (en) | Compositions and methods for the sublingual or buccal administration of therapeutic agents | |
| KR970042553A (ko) | 캠프토테신 유도체 | |
| MXPA02005536A (es) | Acidos aminopropilfosfinicos novedosos. | |
| DE69912952D1 (en) | Cyclosporine | |
| SI2068907T1 (sl) | Z glicerolom povezani pegilirani sladkorji in glikopeptidi | |
| CN101208091A (zh) | 促进口腔吸收的***的固体药制剂 | |
| EP2130548A3 (en) | Growth Hormone Releasing Peptides | |
| RU2000100369A (ru) | Аналоги пептида лг-рф, их применение и содержащие их фармацевтические композиции | |
| WO2001052894A3 (en) | Nasally administrable cyclic peptide compositions | |
| CA2292846A1 (en) | Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them | |
| CA2097192A1 (en) | Bombesin antagonists | |
| JP2005508842A5 (sl) | ||
| SI9420001B (sl) | Polipeptidni antagonisti bombezina | |
| JP2019523260A5 (sl) | ||
| CA1335622C (en) | Bradykinin analogs containing a non-peptide bond | |
| WO2005018657A3 (en) | NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY | |
| WO2005019457A3 (en) | NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY | |
| JP2006505556A5 (sl) | ||
| EP1700608A1 (en) | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain | |
| AR029930A1 (es) | Peptidos analogos de la sustancia p, procesos de sintesis de los mismos, composiciones y el uso de dichos peptidos para la manufactura de un medicamento para el tratamiento de cancer | |
| CN1126999A (zh) | 具有催产素拮抗剂活性的肽类化合物 | |
| EP0507484A1 (en) | A pharmaceutical formulation of aureobasidins | |
| DE10239832A1 (de) | Sarcolysyl-Derivate und Verfahren zu deren Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date |